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Abstract
Alterations of bone metabolism have been observed
in numerous studies of HIV-infected patients. Sex
steroids are known to profoundly influence bone mass
and bone turnover. Hypogonadism is common in
HIV-infection. Therefore, we performed a cross sec-
tional study of 80 male HIV-infected patients without
wasting syndrome, and 20 healthy male controls, in
whom we analyzed urine and serum samples for both
calciotropic hormones and markers of bone metabo-
lism and of endocrine testicular function. Bone miner-
al density (BMD) was assessed by dual-energy X-ray
absorptiometry both in the lumbar spine and Ward’s
triangle of the left hip. None of the patients received
highly-active-antiretroviral-therapy (HAART). Com-
pared to eugonadal HIV-infected patients, subjects
with hypogonadism (n = 32; 40%) showed statistically
significant decrease of serum osteocalcin (p < 0.05)
and elevated urinary excretion of crosslinks (p < 0.05).
However, we found 13 and 15, respectively, patients
with osteopenia (t-score -1.0 to -2.5 SD below nor-
mal) of the lumbar spine. The dissociation between
bone formation and resorption and the reduction of
of BMD (p < 0.05) is stronger expressed in patients
with hypogonadism. Habitual hypogonadism appears
to be of additional relevance for bone metabolism of
male HIV-positive patients prior to HAART.
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INTRODUCTIONS
Alterations of bone metabolism have been observed
in numerous studies of small groups of male patients
infected with HIV. Both hypocalcemic [1, 2] or hyper-
calcemic phases [3, 4, 5, 6] reduced serum osteocalcin
levels [7, 8, 9] and hypoparathyroidism [5, 7, 9] have
been reported. The reduction of bone mineral density
(BMD) has been observed in several studies of HIV-
afflicted patients [10, 11, 12, 13]. Testosterone defi-
ciency is a risk factor for osteoporosis in male and fe-
male patients [14, 15, 16]. Sex hormone deficiency is
among the most frequent endocrine abnormalities in
HIV-1 infected men, and it‘s clinical symptoms (impo-
tence and decreased libido) have been reported in 33
and 67%, respectively [17]. Based on the theory that
sex hormone deficiency is mediated through direct os-
teoblastic and osteoclastic effects, modulation of cy-
tokine milieu, and extraskeletal effects on calcium
homeostasis [2], we performed a cross sectional study
of 80 HIV-1 infected male subjects, in whom we as-
sessed both biochemical markers of bone metabolism
and BMD by dual-energy X-ray absorptiometry
(DEXA). Thus, the aim of this investigation was to
examine the prevalence of hypogonadism in the HIV-
infected outpatients, and to determine the alterations
of bone metabolism in HIV-infected patients with hy-
pogonadism compared to those with eugonadism and
the manifestation of osteopenia in these patients.
PATIENTS
80 male patients with a recently confirmed serodiag-
nosis (including Western blot analysis) of HIV-1 infec-
tion participated in the study. They were examined in
our outpatient clinic (age range 23 to 45 years). At the
time of examination the patients had no concomitant
opportunistic infections; no acute or chronic hepatitis
with increased liver transaminase activities; nor alter-
ations of the liver parenchyma under sonomorpholog-
ical criteria; no wasting symptoms; no gastrointestinal
disorders such as pancreatic insufficiency or malab-
sorption syndrome nor chronic diarrhea. The patients
did not take any drugs known to influence the charac-
teristics of bone metabolism or the endocrine system,
Patients did not receive antiretroviral like protease in-
hibitors or reverse trancriptase inhibitors for addition-
al antiretroviral therapy.. Patients with cytomegaly-as-
sociated chorioretinitis were excluded from the study,
since treatment with Foscarnet or Gangciclovir is
known to affect the serum calcium level [18, 19]. Clini-
cal data are shown in Table 1. Fasting blood samples
were obtained by puncture of a cubital vein. The
serum was frozen and stored at -30°C. 24-h urine
samples were collected after a gelatin-free diet for 24
hoursand stored without additives at -30°C. An age-
matched control group consisting of 20 healthy indi-
viduals ( 20 males, group III) was studied for compari-
son. No inividual performed extreme physical exercise.
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The lymphocyte subpopulations (CD4) were deter-
mined using monoclonal fluorescent antibodies and
the FACscan autoanalyzer (both from Becton-Dickin-
son). Total pyridinolines were measured using a RIA
kit from Biermann, Bad Nauheim, Germany. The ref-
erence value for this kit was set at values lower than 50
nmol/pyd/nmol creatinine. Serum calcium, phos-
phate, creatinine and albumin as well as the urinary ex-
cretion of calcium, phosphate, and creatinine were
measured by standardized laboratory methods. Plasma
PTH (1-84) was determined by radioimmunoassay
(RIA) from the Nichols Institutes, Wijchen, The
Netherlands. Serum osteocalcin was measured using a
commercial RIA kit from Incestar, Stillwater, Min-
nesota, USA. The inter- and intra-assay coefficients of
variation were 5% and 10%, respectively (reference 2,0
to 6,5 pg/ml). Calcitonin was measured using a RIA
kit from Biermann, Bad Nauheim, Germany (normal
values 5-15 pg/ml). Vitamin D concentration: 1,25-di-
hydroxycholecalciferol (1,25 (OH)2D3) in serum was
determined using a RIA from Nichols Diagnostics,
Wijchen, The Netherlands (detection limit 5,0 ng/ml);
25 (OH)D3 was determined using a RIA from Nichols
Diagnostics, Wijchen, The Netherlands (normal values
8-80 ng/ml). The marker of the gonadal axis were
measured by means of commercially available kits:
FSH and LH RIA, (Biermann, Germany); prolactin
and total testosterone RIA, (BYK, Germany).
BMD MEASUREMENTS
The measurement of the bone mineral density (BMD)
was performed using dual-energy X-ray absorptiome-
try (DEXA) of the LUNAR Radiation Corporation,
Madison, Wisconsin, United States. Measurements
were taken at the lumbar spine (L1 to L4 a.p.) and
Ward‘s triangle of the left hip. Low BMD was defined
according to World Health Organization (WHO)
guidelines as a T-score less than -2.5 SD below the
mean of young healthy adults.
STATISTICAL ANALYSIS
Normal distribution of data was analyzed by the Kol-
mogorow-Smirnov normality test.The mean values of
the different groups and their standard deviations
were compared by means of Student' s t-test. Differ-
ences of p < 0,05 were considered statistically signifi-
cant. Data, that showed unequal variance or abnormal
distribution, were analyzed by Mann-Whitney rank
sum test. Statistical analysis was performed using Sta-
tistical Package for Social Science (SPSS) [20].
RESULTS
Age, CD4-cell-count, weight, body mass index, and
the drug treatment are shown in Table 1. with means
± standard deviation of the respective groups. Weight
and body mass index were found to be significantly
lower in the two groups of male HIV-1infected pa-
tients as compared to the control group.
Serum total testosterone was significantly decreased
below the normal range in 32 (40%) male patients
(group I). Group II comprised the 48 male HIV-1 in-
fected subjects with normal testosterone levels. Their
individual FSH, LH and prolactin levels were within
the normal range. The LH and FSH levels of hypogo-
nadal patients ranged near the lower limit and were
significantly decreased compared to the levels of eug-
onadal patients. (Statistical analysis did not show sig-
nificant differences of the steroid markers between
the homosexually or heterosexually active males in the
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Table 1. Biochemical markers and characteristics (mean ±SD) of the male HIV-1 infected subjects with hypogonadism (group
I); HIV-1 infected male eugonadal patients and healthy controls (significance between HIV-1 infected men of group I or II and
controls * p < 0.05) (significance between hypogonadal and eugonadal patients # p < 0.05).
Parameter Group I Group II Group III Range
(n = 32) (n = 48) (n = 20)
HIV-1 HIV-1 Male, control
hypogonadism eugonadism
Weight [kg] 71.4 ± 4.2 * 74.7± 3.6 78.5 ± 4.7
Body mass index [kg/m2] 24.1 ± 2.2 24.9 ±3.1 26.05 ± 5.5
Age [yr] 39.1 ±7.2 35.2 ± 4.3 35.4 ± 4.1
Smoker [total] 10 30 5
Unemployed [total] 8 15 0
Heroin addict 400
Cotrim [total] 15 23 0
Tuberculostatica [total] 120
CD4 cell count [total] 153.5 ± 56.2 *# 235.5 ± 37.5 * 890.0 ± 69.1 610-970 [total]
Prolactin [mIU/ml] 31.1 ± 3.7 27.4 ± 2.05 30.8 ± 5.3 20-50 mIU/ml]
FSH [mIU/ml] 2.15 ± 1.4 *# 4.2 ± 3.1 3.6 ± 2.6 2.2-19.6 [mIU/ml]
LH [mIU/ml] 1.9 ± 2.5 *# 3.2 ± 2.2 3.2 ± 1.4 2.5-99.5 [mIU/ml]
Testosterone total [ng/dl] 149.2 ± 62.5 *# 601.0 ±73.2 534.4 ± 45.8 300-1000 [ng/dl]
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subjects with determined hypogonadism or eugo-
nadism. Therefore patients were pooled for suitable
analysis.
Serum levels of PTH were significantly reduced (p
< 0.05) in group I compared to the male healthy con-
trols. The serum total calcium was also significantly
decreased compared to controls (p < 0.05). Serum os-
teocalcin was significantly decreased in male HIV-1 in-
fected patients of group I (p < 0.01).
The serum levels of 25 (OH)D in HIV-1 infected
patients were decreased but did not significantly differ
from those of controls. However, the 1,25-dihydroxy-
cholecalciferol 1,25 (OH)2D3 was significantly re-
duced in both group I and group II.
The excretion rates of crosslinks in the 24 h sam-
ples of the groups are shown in Table 2. Increased uri-
nary crosslink excretion was also observed in male
HIV-1 subjects (p < 0.05) likewise an elevated urinary
calcium-excretion (p < 0.05). However, there was an
increased crosslink excretion in HIV-1 infected sub-
jects with hypogonadism compared to those patients
with normal testicular function (p < 0.05). Similary, an
elevated urinary excretion of calcium was observed (p
< 0.05).
BMD values of the lumbar spine differed signifi-
cantly between HIV-1 infected patients and controls (p
< 0.05) at all sites measured (Table 3), whereas BMD
measurements of the Ward’s triangle were not distinct
between the two groups of HIV subjects and the con-
trols.
DISCUSSION
Our study showed significantly lower BMD of the
lumbar spine in HIV-1 infected male patients with hy-
pogonadism as compared with BMD values at the
spine in control subjects. These findings are in line
with the observation that a certain proportion of
HIV-patients presents a loss of bone mineral density
at the spine, but with normal or near normal BMD
values at Ward’s triangle. According to prior studies
[10, 12, 13] a decrease in BMD of the lumbar spine is
common in HIV-afflicted males. Data on reduced
BMD of Ward‘s triangle or hip are limited. Paton et al.
did not find detectable loss of BMD in Hip of 45
HIV-infected patients [10]. However, Fairfield et al.
observed reduced BMD both in eugonadal men with
acquired immune deficiency related wasting syndrome.
Total hip scores were less than -1.0 in 33% of men
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Table 2. Biochemical markers and characteristics (mean ±SD) of bone metabolism of the male HIV-1 infected patients with hy-
pogonadism (group I); ( significance between HIV-1infected men of group I or II and controls * p < 0.05) (significance be-
tween hypogonadal and eugonadal patients # p < 0.05).
Parameter Group I Group II Group III Range
(n = 32) (n = 48) (n = 20)
HIV-1 HIV-1 male controls
Hypogonadism Eugonadism
Serum Ca [mmol/l] 2.10 ± 0.107 * 2.21 ± 0.1 2.6 ± 0.23 2.20-2.65 [mmol/l]
Serum D 1,25(OH2)D [pg/ml] 27.9 ± 9.7 * 31.5 ± 7.5 * 67.45 ± 4.25 44-74 [pg/ml]
Serum D 25(OH)D [ng/ml] 24.3 ±10.3 *# 46.7 ± 14.1 * 69.5 ± 13.5 8-80 [ng/ml]
PTH [pg/ml] 19.6 ± 8.9 * 28.5 ± 5.2 * 37.8 ± 4.8 10-65 [pg/ml]
Osteocalcin [ng/ml] 2.35 ± 0.57 * # 3.58 ± 0.53 3.6 ± 0.39 2.0-6.5 [ng/ml]
Creatinine [mg/dl] 0.89 ± 0.1 0.99 ± 0.14 0.87 ± 0.15 0.68-1.09 mg/dl
Albumine [g/l] 38.9 ± 6.2 41.3 ± 5.7 46.5 ± 3.7 35.8-50.6 [g/l]
Crosslinks [nmol/pyd/mmol Crea] 79.0± 11.7 *# 65.71 ± 10.2 31.5 ± 6.2 < 50
Urinary Ca [mmol/24h] 7.72 ± 0.75 *# 4.47 ± 0.69 1.07 ± 0.31 < 6.2 [mmol/l]
Table 3. BMD measurements performed by LUNAR dual-energy X-ray absorptiometry (DEXA) in 80 HIV-1 infected male pa-
tients (group I 32 hypogonadal patients; group II 48 eugonadal patients) and 20 mal controls (group III). ( significance between
HIV-1 infected men of group I or II and controls * p < 0.05) (significance between hypogonadal and eugonadal patients # p <
0.05).
Parameter Group I Group II Group III
(n = 32) (n = 48) (n = 20)
HIV-1 Hypogonadism HIV-1 Eugonadism male controls
BMD lumbar spine [g/cm2] 1.018 * ± 0.031 1.037 ± 0.024 1.081 ± 0.026
BMD Ward`s triangle [g/cm2] 0.959 ± 0.052 0.9667 ± 0.047 1.002 ±0.043
Osteopenia lumbar spine 13 15 0
[t-score -1.0 to -2.5 SD below normal]
Osteoporosis Ward’s triangle 10 0
[t-score < 2.5 SD below normal]
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of BMD at lumbar spine in group 1 of the current pa-
tients provides strong evidence that additional hypog-
onadism has an important influence on individual
BMD in this region. In contrast, osteopenia in Ward’s
Triangle could not be confirmed in our eugonadal or
hypogonadal HIV-1 infected male subjects. It is inter-
esting that hypogonadism is common in AIDS-pa-
tients with wasting syndrome [23, 24]. Wasting syn-
drome has been reported as an independent risk factor
for reduction of BMD both in male and female pa-
tients [21, 25]. Therefore, we excluded each patient
with weight loss in the recent case history. To date, it is
not clear whether our findings translate into a general
recommendation for hormone replacement directed
only to hypogonadal HIV-1 infected subjects. Over a
12 week treatment period with testosterone eugonadal
AIDS patients improved also their BMD at the lumbar
spine. On the other hand, the anabolic strategies led to
improve muscle mass and BMD [21]. Megestrol ac-
etate treatment resulted in robust weight gain and acr-
rural of lean body mass in men with HIV-assiciated
wasting. Addition of a conventional dose of testos-
terone preserved sexual functioning but did not signif-
icantly increase the proportion of weight gained as
lean body mass, suggesting that either Megestrol ac-
etate induced hypogonadism is not a significant deter-
minant of the partitioning of weight gain or higher
dose of of testosterone is required to overcome the
suppressive effects of Megestrol acetate on testos-
terone production or action [22]. The contribution of
hypogonadism on bone metabolism is linked to the ef-
fect of hormone replacement therapy on bone metab-
olism mediated trough direct osteoblastic and osteo-
clastic effects [21] or modulation of cytokine milieu,
and extraskeletal effects on calcium homeostasis [14,
15]. We detected a decrease of osteocalcin in hypogo-
nadal patients. Several studies have assessed biochemi-
cal marker of bone formation and resorption in pa-
tients with HIV [7, 8, 9, 26, 27]. Serum osteocalcin
were lowered in advanced stages of disease and were
positively correlated with CD4 cell counts [8, 9, 19].
Another small study reported a decrease of serum os-
teocalcin concentration in 16 patients with HIV as
compared to normal controls, particulary with ongo-
ing HIV-1 infection too more than 2 years [29]. A pos-
itive correlation between osteocalcin and the number
of CD4 cells was described in a male group of 65
HIV-1 infected patients and was independent of exist-
ing normal or reduced vitamin 1,25 (OH)2D levels
and reduced albumin values and as a marker for severe
nutritional protein deficiency [9]. The loss of CD4
cells is associated with reduced bone formation rate
[9] and significantly differed between group I and II.
Our results in the HIV-1 infected subjects groups were
in aggreement with data of male patients recently pre-
sented [8, 9, 25, 27]. Additionally, serum levels of
propeptide of type I collagen (PICP), a marker of
bone formation, were found to be decreased in 13 pa-
tients with AIDS as compared with normal controls or
patients with HIV-1 infection [26]. It is known, that
treatment with recombinant human growth hormone
(rhGH) significantly increased PICP levels in normal
subjects and in patients with AIDS [26]. In a cross-
sectional study, Aukrust et al. [19] evaluated bone
markers and inflammatory cytokines in 73 HIV-1 in-
fected patients. As HIV-1 infection advanced, serum
levels of osteocalcin decreased and C-telopeptide, a
serum marker of bone resorption, increased. Serum
levels of soluble TNFα receptor negatively correlated
with serum concentrations of osteocalcin and posi-
tively with serum levels of C-telopeptide[19]. The no-
tion of increased bone resorption rate in HIV-1 in-
fected patients is underlined by our findings of in-
creased urinary crosslink excretion.
In hypogonadal HIV-infected group we observed a
strong dissociation between markers of bone forma-
tion and bone resorption. The reasons for these
changes in markers of bone remodeling are unclear.
Although the activation of direct HIV-mediated ef-
fects on osteoblasts and osteoclasts may be involved, it
is temping to hypothesize that these findings at least
partly reflect activity of TNFα and or other proin-
flammatory cytokine systems [28]. It has been suggest-
ed that therapy inhibiting activation of the transcrip-
tional factor nulcear factor-α, a potent inducer of sev-
eral proinflammatory cytokines, may hold therapeutic
potential in the treatment of osteoporosis and other
bone disorders [30]. However, findings suggest a re-
synchronization of bone formation and resorption
during the highly-active antiretroviral therapy
(HAART) in those patients and support the idea of an
interaction between cytokines and bone remodeling
[25, 27].
Decreased vitamin 1,25 (OH)2D3 levels were found
in all of our HIV-infected patients. Haug et al. [30]
similary reported reduced 1,25(OH)2D3 and (slightly)
reduced 25(OH)D levels in HIV-1 infected patients
with symptomatic AIDS. In comparison with a group
of asymptomatic HIV-1 patients, this reduction was
statistically significant. Reduced vitamin D levels are in
part responsible for an increased bone turnover rate.
These findings of reduced 1,25(OH)2D3 are indepen-
dently of the gonadal function and may be influenced
by altered PTH levels. The slightly reduced 25(OH)D
levels in both hypo- and eugonadal subjects can be ex-
plained by malnutrition and malabsorption of HIV-1
patients.
Despite low vitamin D levels, the serum PTH val-
ues of HIV-1 patients were in the low normal range.
This has been corroberated by several studies [2, 8, 9,
31, 32, 33] and was also observed in our first group. In
a large study on hypocalcemia in HIV-1 infection, in-
appropriately low PTH secretion accounted for as
many as one-third of cases with hypocalcemia [2].
Hypogonadism is common among HIV-infected
men, although the anticipated age-associated reduc-
tions were not seen. Furthermore, hepatitis C infec-
tion and other factors, such as injection drug use, were
associated with reduced testosterone levels, whereas
HIV status was not associated with hypogonadism.
Therefore, hypogonadism may be common among
older HIV-infected men but is more often associated
with comorbid conditions than with HIV infection it-
self [34]. The first group of our study included four
heroin addicts. From this reason the hypogonadism of
these (older) patients may be particulary a result from
drug abuse.
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ed with antiretroviral therapy particulary with protease
inhibitors. However, we here present male patients,
which did not receive protease-inhibitors until time of
measurement. Nolan et al. found no evidence of ac-
celerated bone loss in patients treated with nelfinavir
opr indinavir-containing HAART [33]. Carr et al. pre-
sent the data of DEXA in 221 HIV-1infected men
who were treated with protease inhibitores or reverse
transcriptase inhibitors. Osteoporosis was found in
3% and osteopenia in 44 % of the patients [12]. There
was no independent association with other parameters,
including type or duration of antiretroviral therapy
and lipodystrophy at any site. Reduced BMD was asso-
ciated with lower weight prior to commencing anti-
retroviral therapy, whereas low spinal BMD was asso-
ciated mostly with higher lactate. However, reduction
of BMD of male HIV-1infected patients of our study
appeared to be stronger. In HIV-infected patients,
higher viral load was associated with reduced andro-
gen levels, whereas use of HAART was not [34].
However, a study from Crum-Cianflone et al presents
no association between erectile dysfunction or hypog-
onadism with the current, past, or cumulative use of
HIV medications [35].
This study has some limitations, including the mea-
surement of total testosterone without aspect of the
free testosterone levels that are considered to be more
accurate concerning the link of hypogonadism and
bone metabolism. In assessing androgen levels among
HIV-infected patients, consideration should be given
to measuring levels of free (bioavailable) testosterone,
unbound to sex hormone-binding globulin. Increased
sex hormone-binding globulin levels among HIV-in-
fected patients may result in relative increases in total
testosterone levels that do not reflect bioavaible or
free testosterone [24, 37, 38].
What are the clinical consequences of androgen de-
ficiency in HIV-infected patients? Among HIV-infect-
ed men, hypogonadism is associated with reduced
muscle mass, decreased strength, and decreased func-
tional status, bone loss and depression [38]. Treatment
of hypogonadal HIV-infected men has been shown to
increase muscle mass, strength, and quality of life and
to improve depression indices and bone mass [37].
Three clinical trials to date have evaluated the use
of a bisphosphonate in HIV-infected persons. The tri-
als showed a marked increase in bone mineral density
in patients taking alendronate versus those in the con-
trol groups Dosing restrictions complicate the use of
these agents; diet, exercise, and calcium supplementa-
tion remain the foremost recommended strategies to
prevent bone loss. The use of estrogen, testosterone,
calcitonin, and teriparatide is less studied in HIV-posi-
tive patients, but may be considered in select cases
[39].
In conclusion, we found a reduction of BMD at the
lumbar spine in male HIV-1infected patients. The inci-
dence of osteopenia is elevated in this patient group
with even stroner decrease of BMD in patients with
hypogonadism. The BMD of Ward’s triangle was not
affected. A dissociation of bone formation and re-
sorption rate was observed. The loss of bone mineral
density also occured in HAART-naive patients. The
habitual hypogonadism appears to be of additional
relevance for bone metabolism of male HIV-positive
patients prior to start of highly active antiretroviral
therapy.
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